Sandra E. Dillahunt

Array ( [id] => 8779688 [patent_doc_number] => 20130101663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-25 [patent_title] => 'Soluble tumor necrosis factor receptor (sTNF-R) used as a targeting agent to treat arthritis and other diseases' [patent_app_type] => utility [patent_app_number] => 13/507897 [patent_app_country] => US [patent_app_date] => 2012-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6108 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13507897 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9625994 [patent_doc_number] => 08795669 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-05 [patent_title] => 'Stabilized formulations containing anti-PCSK9 antibodies' [patent_app_type] => utility [patent_app_number] => 13/559862 [patent_app_country] => US [patent_app_date] => 2012-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22198 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13559862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8891125 [patent_doc_number] => 20130164309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-27 [patent_title] => 'ANTIBODIES TO THE B12-TRANSCOBALAMIN RECEPTOR' [patent_app_type] => utility [patent_app_number] => 13/554780 [patent_app_country] => US [patent_app_date] => 2012-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 46644 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13554780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8814224 [patent_doc_number] => 20130115269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-09 [patent_title] => 'Anti-tumor necrosis factor alpha (TNF-a) antibody used as a targeting agent to treat arthritis and other diseases' [patent_app_type] => utility [patent_app_number] => 13/507660 [patent_app_country] => US [patent_app_date] => 2012-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6883 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13507660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11793117 [patent_doc_number] => 09402807 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-02 [patent_title] => 'Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device' [patent_app_type] => utility [patent_app_number] => 13/539019 [patent_app_country] => US [patent_app_date] => 2012-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 23910 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13539019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11183622 [patent_doc_number] => 09415004 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-08-16 [patent_title] => 'Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device' [patent_app_type] => utility [patent_app_number] => 13/538912 [patent_app_country] => US [patent_app_date] => 2012-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 23924 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13538912 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771094 [patent_doc_number] => 20140294758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'LIGHT CHAIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/129133 [patent_app_country] => US [patent_app_date] => 2012-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 21533 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14129133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9491123 [patent_doc_number] => 20140141528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE' [patent_app_type] => utility [patent_app_number] => 14/128188 [patent_app_country] => US [patent_app_date] => 2012-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25773 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14128188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8452782 [patent_doc_number] => 20120263728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-18 [patent_title] => 'METHOD TO GENERATE ANTIBODIES TO ION CHANNELS' [patent_app_type] => utility [patent_app_number] => 13/523104 [patent_app_country] => US [patent_app_date] => 2012-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 13824 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13523104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9448890 [patent_doc_number] => 20140120059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'IMMUNITY INDUCING AGENT' [patent_app_type] => utility [patent_app_number] => 14/118271 [patent_app_country] => US [patent_app_date] => 2012-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13341 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14118271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9517713 [patent_doc_number] => 20140154206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-05 [patent_title] => 'IMMUNITY INDUCTION AGENT' [patent_app_type] => utility [patent_app_number] => 14/118417 [patent_app_country] => US [patent_app_date] => 2012-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13265 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14118417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9448942 [patent_doc_number] => 20140120111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-01 [patent_title] => 'TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONS USING ANTAGONISTS OF SGK1 ACTIVITY' [patent_app_type] => utility [patent_app_number] => 14/118261 [patent_app_country] => US [patent_app_date] => 2012-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 10125 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14118261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441421 [patent_doc_number] => 20120258038 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'USES OF APOPTOTIC CELL-TARGETING PEPTIDES, LABEL SUBSTANCES AND LIPOSOMES CONTAINING A THERAPEUTIC AGENT FOR PREVENTING, TREATING OR THERAPEUTICALLY DIAGNOSING APOPTOSIS-RELATED DISEASES' [patent_app_type] => utility [patent_app_number] => 13/470076 [patent_app_country] => US [patent_app_date] => 2012-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10338 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13470076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8509177 [patent_doc_number] => 20120308584 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-06 [patent_title] => 'PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/466875 [patent_app_country] => US [patent_app_date] => 2012-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 29311 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13466875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8720197 [patent_doc_number] => 20130071414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-21 [patent_title] => 'ENGINEERED CD19-SPECIFIC T LYMPHOCYTES THAT COEXPRESS IL-15 AND AN INDUCIBLE CASPASE-9 BASED SUICIDE GENE FOR THE TREATMENT OF B-CELL MALIGNANCIES' [patent_app_type] => utility [patent_app_number] => 13/458085 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 15278 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13458085 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8779578 [patent_doc_number] => 20130101553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-25 [patent_title] => 'INDUCING INACTIVATION OF FIBROGENIC MYOFIBROBLASTS' [patent_app_type] => utility [patent_app_number] => 13/450400 [patent_app_country] => US [patent_app_date] => 2012-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 16201 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13450400 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9273111 [patent_doc_number] => 08637038 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-01-28 [patent_title] => 'Methods for inhibiting allograft rejection' [patent_app_type] => utility [patent_app_number] => 13/444684 [patent_app_country] => US [patent_app_date] => 2012-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 14471 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 112 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13444684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8476642 [patent_doc_number] => 20120276049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-01 [patent_title] => 'Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences' [patent_app_type] => utility [patent_app_number] => 13/442057 [patent_app_country] => US [patent_app_date] => 2012-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 24400 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13442057 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8733721 [patent_doc_number] => 20130079290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-28 [patent_title] => 'S1P ANTAGONISTS AS ADJUNCT OCULAR HYPOTENSIVES' [patent_app_type] => utility [patent_app_number] => 13/430340 [patent_app_country] => US [patent_app_date] => 2012-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4866 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13430340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9568583 [patent_doc_number] => 20140186295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-03 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 14/004438 [patent_app_country] => US [patent_app_date] => 2012-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 26469 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14004438 [rel_patent_id] =>[rel_patent_doc_number] =>)